文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

帕瑞替尼是强效ACVR1抑制剂,对骨髓纤维化患者有显著贫血获益

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
PubMed 文献 · Blood Adv · 2023-01-01

在细胞减少性骨髓纤维化患者中,3期PERSIST-2研究显示JAK2/IRAK1抑制剂帕瑞替尼与贫血获益相关。帕瑞替尼抑制ACVR1的效力(IC50=16.7 nM;Cmax:IC50=12.7)强于莫美替尼、非德拉替尼和芦可替尼。基线未达输血非依赖的患者中,帕瑞替尼组较最佳可用治疗组更多实现输血非依赖(37% vs 7%,P=.001)。

要点

  • 帕瑞替尼抑制ACVR1的IC50=16.7 nM,Cmax:IC50=12.7,效力强于莫美替尼、非德拉替尼和芦可替尼。
  • PERSIST-2中基线未达输血非依赖者,帕瑞替尼组37%实现输血非依赖,最佳可用治疗组7%(P=.001)。
  • 帕瑞替尼组49%输血负荷降低≥50%,最佳可用治疗组9%(P<.0001)。

核心结论

  • JAK2/IRAK1抑制剂帕瑞替尼的贫血获益可能是其强效抑制ACVR1的结果。

研究设计与样本

  • 基于3期PERSIST-2研究,评估帕瑞替尼对输血非依赖的影响,并体外比较帕瑞替尼与其他JAK2抑制剂对ACVR1的抑制效力。

主要发现

  • 帕瑞替尼抑制ACVR1的IC50=16.7 nM,Cmax:IC50=12.7;莫美替尼IC50=52.5 nM,Cmax:IC50=3.2;非德拉替尼IC50=273 nM,Cmax:IC50=1.0;芦可替尼IC50>1000,Cmax:IC50<0.01。
  • 帕瑞替尼抑制ACVR1的活性通过下游SMAD信号抑制及显著抑制铁调素生成得到佐证。
  • PERSIST-2中基线按Gale标准未达输血非依赖的患者,帕瑞替尼组37%实现输血非依赖,最佳可用治疗组7%(P=.001)。
  • 帕瑞替尼组49%输血负荷降低≥50%,最佳可用治疗组9%(P<.0001)。

关键数值与推荐

  • 帕瑞替尼抑制ACVR1的IC50=16.7 nM,Cmax:IC50=12.7。
  • 莫美替尼抑制ACVR1的IC50=52.5 nM,Cmax:IC50=3.2。
  • 非德拉替尼抑制ACVR1的IC50=273 nM,Cmax:IC50=1.0。
  • 芦可替尼抑制ACVR1的IC50>1000,Cmax:IC50<0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with cytopenic myelofibrosis, treatment with the JAK2/IRAK1 inhibitor pacritinib was associated with anemia benefit in the phase 3 PERSIST-2 study. The impact of pacritinib on transfusion independence (TI) has not been previously described, nor has the mechanism by which pacritinib improves anemia been elucidated. Because it has been previously postulated that inhibition of activin A receptor, type 1 (ACVR1)/activin receptor-like kinase-2 improves anemia in patients with myelofibrosis via suppression of hepcidin production, we assessed the relative inhibitory potency of pacritinib compared with other JAK2 inhibitors against ACVR1. Pacritinib inhibited ACVR1 with greater potency (half-maximal inhibitory concentration [IC50] = 16.7 nM; Cmax:IC50 = 12.7) than momelotinib (IC50 = 52.5 nM; Cmax:IC50 = 3.2), fedratinib (IC50 = 273 nM; Cmax:IC50 = 1.0), or ruxolitinib (IC50 > 1000; Cmax:IC50 < 0.01). Pacritinib's inhibitory activity against ACVR1 was corroborated via inhibition of downstream SMAD signaling in conjunction with marked suppression of hepcidin production. Among patients on PERSIST-2 who were not transfusion independent at baseline based on Gale criteria, a significantly greater proportion achieved TI on pacritinib compared with those treated on best available therapy (37% vs 7%, P = .001), and significantly more had a ≥50% reduction in transfusion burden (49% vs 9%, P < .0001). These data indicate that the anemia benefit of the JAK2/IRAK1 inhibitor pacritinib may be a function of potent ACVR1 inhibition.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Oh ST, Mesa RA, Harrison CN, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023. PMID: 37552106. doi:10.1182/bloodadvances.2023010151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。